

# Resource Guide

KANJINTI® is a biosimilar to Herceptin®  
backed by Amgen expertise<sup>1</sup>

## INDICATIONS

### Adjuvant Breast Cancer

KANJINTI® is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature\*) breast cancer:

- As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel
- As part of treatment with docetaxel and carboplatin
- As a single agent following multi-modality anthracycline-based therapy

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

\*High-risk is defined as ER/PR positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3.

### Metastatic Breast Cancer

KANJINTI® is indicated:

- In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer
- As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

### Metastatic Gastric Cancer

KANJINTI® is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease.

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

## Boxed WARNINGS and Additional Important Safety Information

### Cardiomyopathy

- Trastuzumab products administration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens
- Evaluate left ventricular function in all patients prior to and during treatment with KANJINTI®. Discontinue KANJINTI® treatment in patients receiving adjuvant therapy and withhold KANJINTI® in patients with metastatic disease for clinically significant decrease in left ventricular function

Please see accompanying full indications on pages 2 and 3 and Important Safety Information, including Boxed WARNINGS, on pages 12 and 13, and full Prescribing Information.



TABLE OF CONTENTS

SUPPLY.....3

RECONSTITUTION AND PREPARATION INSTRUCTIONS.....4

IV INFUSION DURATION, DOSING, AND SCHEDULES.....6

CODING.....7

PHYSICIAN CODING FORM.....8

HOSPITAL CODING FORM.....9

KANJINTI® PRODUCT FACT SHEET.....10

SUPPORT PROGRAMS.....11

IMPORTANT SAFETY INFORMATION.....12

Amgen can provide support for institutions, including education, reimbursement assistance, and to help facilitate transitioning to KANJINTI® (trastuzumab-anns).

CALL 1-888-4ASSIST (888-427-7478) Monday to Friday, 9:00 AM to 8:00 PM ET, OR VISIT AMGENASSIST360.COM

Boxed WARNINGS and Additional Important Safety Information (continued)

- Infusion Reactions; Pulmonary Toxicity
- Trastuzumab products administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration. Interrupt KANJINTI® infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue KANJINTI® for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome
- Embryo-Fetal Toxicity
- Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception

Please see accompanying Important Safety Information, including Boxed WARNINGS, and full Prescribing Information.

SUPPLY

SUPPLY¹

KANJINTI® in powder form is a sterile, white to pale yellow, preservative-free lyophilized powder in a vial.

Each carton of KANJINTI® contains either:

- **150 mg single-dose vial of KANJINTI®**  
(NDC 55513-141-01)¹
- **420 mg multi-dose\* vial of KANJINTI®**  
(NDC 55513-132-01)  
\*Multi-dose when reconstituted with bacteriostatic water for injection
- **420 mg multi-dose† vial (kit) of KANJINTI® and one vial (20 mL) BWFI**  
(NDC 55513-164-01)  
†Multi-dose when reconstituted with included bacteriostatic water for injection (BWFI)



RECONSTITUTION AND PREPARATION INSTRUCTIONS

RECONSTITUTION OF KANJINTI® (TRASTUZUMAB-ANNS) VIALS<sup>1,2</sup>

SUPPLY AND STORAGE	
Multiple-Dose Vials*	
Reconstituted with 20 mL BWFI,† USP containing 1.1% benzyl alcohol	Diluted in infusion bag with 250 mL of 0.9% sodium chloride injection, USP
Refrigerate at	
2° to 8°C (36° to 46°F)	2° to 8°C (36° to 46°F)
Maximum time: 28 days	Maximum time: 24 hours

\*Single-use vial when reconstituted with Sterile Water for Injection  
†Bacteriostatic water for injection, USP, containing 0.9%-1.1% benzyl alcohol as a preservative is allowable

If you have any questions about the reconstitution and preparation of KANJINTI®, refer to the package insert or call 1-800-77-AMGEN (1-800-772-6436). For additional information and resources, please visit KANJINTI.com

Boxed WARNINGS and Additional Important Safety Information (continued)

Cardiomyopathy

- Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. In a pivotal adjuvant breast cancer trial, one patient who developed CHF died of cardiomyopathy

Please see accompanying Important Safety Information, including Boxed WARNINGS, and full Prescribing Information.

RECONSTITUTION AND PREPARATION INSTRUCTIONS  
(continued)

FOR RECONSTITUTION<sup>1</sup>

Use appropriate aseptic technique when performing the following reconstitution steps:



Using a sterile syringe, slowly inject the (20 mL) of diluent into the vial containing the lyophilized cake of KANJINTI®. The stream of diluent should be directed into the lyophilized cake. The reconstituted vial yields a solution for multiple-dose use, containing 21 mg/mL trastuzumab-anns KANJINTI® when BWFI is used to reconstitute.



Swirl the vial gently to aid reconstitution. **DO NOT SHAKE.** Slight foaming of the product may be present upon reconstitution. Allow the vial to stand undisturbed for approximately 5 minutes.

Inspect visually for particulates and discoloration prior to administration. The solution should be free of visible particulates, clear to slightly opalescent, and colorless to pale yellow.




Store KANJINTI® reconstituted with diluent in the refrigerator at 2°C to 8°C (36°F to 46°F); discard unused KANJINTI® after 28 days. If KANJINTI® is reconstituted with SWFI without preservative, use immediately and discard any unused portion.




**DO NOT FREEZE.**

FOR DILUTION<sup>1</sup>



Determine the dose (mg) of KANJINTI®. Calculate the volume of the 21 mg/mL reconstituted KANJINTI® solution needed, withdraw this amount from the vial and add it to an infusion bag containing 250 mL of 0.9% Sodium Chloride, USP. **DO NOT USE DEXTROSE (5%) SOLUTION.**




Gently invert the bag to mix the solution. The solution of KANJINTI® for infusion, diluted in polyvinylchloride or polyethylene bags containing 0.9% Sodium Chloride Injection, USP, should be stored at 2° to 8°C (36° to 46°F) for no more than 24 hours prior to use. This storage time is additional to the time allowed for the reconstituted vials.<sup>1</sup>




**DO NOT FREEZE.**

Boxed WARNINGS and Additional Important Safety Information (continued)


- Trastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death
- Trastuzumab products can also cause asymptomatic decline in left ventricular ejection fraction (LVEF)
- Discontinue KANJINTI® treatment in patients receiving adjuvant breast cancer therapy and withhold KANJINTI® in patients with metastatic disease for clinically significant decrease in left ventricular function



IV INFUSION DURATION, DOSING, AND SCHEDULES



\*Within 3 weeks following completion of all chemotherapy.



IV = intravenous; QW = once a week; Q3W = once every 3 weeks.

Boxed WARNINGS and Additional Important Safety Information (continued)

Cardiac Monitoring

- Evaluate cardiac function prior to and during treatment. For adjuvant breast cancer therapy, also evaluate cardiac function after completion of KANJINTI®
- Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan

Please see accompanying Important Safety Information, including Boxed WARNINGS, and full Prescribing Information.

GENERAL CODING INFORMATION

NATIONAL DRUG CODES (NDCs) <sup>1</sup>	
BILLING	Each single-dose carton contains one vial of KANJINTI® (150 mg trastuzumab-anns) NDC 55513-141-01
	Each multi-dose carton contains one vial of KANJINTI® (420 mg trastuzumab-anns) NDC 55513-132-01
	Each multi-dose carton (kit) contains one vial of KANJINTI® (420 mg trastuzumab-anns) and one vial of BWFI (20 mL) NDC 55513-164-01


BREAST CANCER		
ICD-10-CM <sup>3</sup>	Malignant neoplasm of the breast	
	Female breast	Male breast
	C50.011 - C50.012, C50.019	C50.021 - C50.022, C50.029
	C50.111 - C50.112, C50.119	C50.121 - C50.122, C50.129
	C50.211 - C50.212, C50.219	C50.221 - C50.222, C50.229
	C50.311 - C50.312, C50.319	C50.321 - C50.322, C50.329
	C50.411 - C50.412, C50.419	C50.421 - C50.422, C50.429
	C50.511 - C50.512, C50.519	C50.521 - C50.522, C50.529
	C50.611 - C50.612, C50.619	C50.621 - C50.622, C50.629
	C50.811 - C50.812, C50.819	C50.821 - C50.822, C50.829
HCPCS <sup>4</sup>	Q5117 injection, trastuzumab-anns, biosimilar, (KANJINTI®), 10 mg	
	96413: Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug.	
CPT <sup>5</sup>	96415: Chemotherapy administration, intravenous infusion technique; each additional hour. Must be listed separately in addition to code for primary procedure.	
	96417: Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to one hour. Must be listed separately in addition to code for primary procedure.	

METASTATIC GASTRIC CANCER					
ICD-10-CM <sup>3</sup>	Malignant neoplasm of the stomach				
	C16.0	C16.2	C16.4	C16.6	C16.8
	C16.1	C16.3	C16.5	C16.7	C16.9
HCPCS <sup>4</sup>	Q5117 injection, trastuzumab-anns, biosimilar, (KANJINTI®), 10 mg				
CPT <sup>5</sup>	96413: Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug.				
	96415: Chemotherapy administration, intravenous infusion technique; each additional hour. Must be listed separately in addition to code for primary procedure.				
	96417: Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to one hour. Must be listed separately in addition to code for primary procedure.				

The information provided in this document is of a general nature and for informational purposes only; it is not intended to be comprehensive or instructive. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and appropriate coding for his/her own patients and procedures. In no way should the information provided in this document be considered a guarantee of coverage or reimbursement for any product or service.  
BWFI = bacteriostatic water for injection; ICD = international classification of diseases;  
HCPCS = healthcare common procedure coding system; CPT = current procedural terminology.

Boxed WARNINGS and Additional Important Safety Information (continued)

- Monitor frequently for decreased left ventricular function during and after KANJINTI® treatment
- Monitor more frequently if KANJINTI® is withheld for significant left ventricular cardiac dysfunction





PHYSICIAN CODING FORM

The CMS 1500 for Physician Office

Sample CMS 1500 Form — Physician Office Administration

HEALTH INSURANCE CLAIM FORM  
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE  
☐ (Medicare#)

MEDICAID  
☐ (Medicaid#)

TRICARE  
☐ (ID#/DoD#)

CHAMPVA  
☐ (Member ID#)

GROUP HEALTH PLAN  
☐ (ID#)

FECA  
☐ (ID#)

BLK LUNG  
☐ (ID#)

OTHER  
☐ (ID#)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)  
Doe, John D

3. PATIENT'S BIRTH DATE  
MM DD YY  
01 01 11

4. INSURED'S NAME (Last Name, First Name, Middle Initial)  
Doe, John D

5. PATIENT'S ADDRESS (No., Street)  
5555 Any Street

6. PATIENT RELATIONSHIP TO INSURED  
Self ☐ Spouse ☐ Child ☐ Other ☐

7. INSURED'S ADDRESS (No., Street)  
CITY  
Anytown

8. RESERVED FOR NUCC USE

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)

10. IS PATIENT'S CONDITION RELATED TO:  
a. OTHER INSURED'S POLICY OR GROUP NUMBER  
b. RESERVED FOR NUCC USE  
c. RESERVED FOR NUCC USE  
d. INSURANCE PLAN NAME OR PROGRAM NAME

11. INSURED'S POLICY GROUP OR FECA NUMBER  
a. INSURED'S DATE OF BIRTH  
MM DD YY  
M F  
b. OTHER CLAIM ID (Designated by NUCC)  
c. INSURANCE PLAN NAME OR PROGRAM NAME  
d. IS THERE ANOTHER HEALTH BENEFIT PLAN?  
☐ YES ☐ NO If yes, complete items 9, 9a, and 9d.

12. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.

13. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP)  
MM DD YY  
01 01 11

14. OTHER DATE  
MM DD YY

15. NAME OF REFERRING PROVIDER OR OTHER SOURCE  
17a. NPI  
17b. NPI

16. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)  
Brand Name Molecule Name NDC ### Dose Administered  
XXX.XX

17. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24.3)  
A. ICD Ind. B. L C. L D. L E. L F. L G. L H. L I. L J. L

18. PRIOR AUTHORIZATION NUMBER

19. DATE(S) OF SERVICE From To  
MM DD YY MM DD YY  
01 01 11 01 01 11

20. B. PLACE OF SERVICE  
C. SERVICE EMG  
D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances)  
CPT/HCPCS MODIFIER  
Q5117

21. DIAGNOSIS CODE (BOX 21)  
Document appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Line A — primary diagnosis code.

22. DIAGNOSIS CODE (BOX 24E)  
Specify diagnosis, from Box 21, relating to each CPT/HCPCS code listed in Box 24D.

23. SERVICE UNITS (BOX 24G)  
Report units of service per KANJINTI® label and per local payer policy as appropriate.

24. PROCEDURE CODE (BOX 24D)  
Use CPT code representing procedure performed. Healthcare providers should consult the payer or Medicare contractor to determine which code is most appropriate for administration of KANJINTI®.

25. FEDERAL TAX I.D. NUMBER

26. SIGNMENT? (999-300)  
NO

27. TOTAL CHARGE  
\$

28. AMOUNT PAID  
\$

29. Rsvd for NUCC Use

30. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)

31. SERVICE FACILITY LOCATION INFORMATION  
a. NPI b. NPI

32. BILLING PROVIDER INFO & PH # ( )

33. SIGNATURE OF PHYSICIAN OR SUPPLIER

34. DATE

35. NPI

36. NPI

37. NPI

38. NPI

39. NPI

40. NPI

41. NPI

42. NPI

43. NPI

44. NPI

45. NPI

46. NPI

47. NPI

48. NPI

49. NPI

50. NPI

51. NPI

52. NPI

53. NPI

54. NPI

55. NPI

56. NPI

57. NPI

58. NPI

59. NPI

60. NPI

61. NPI

62. NPI

63. NPI

64. NPI

65. NPI

66. NPI

67. NPI

68. NPI

69. NPI

70. NPI

71. NPI

72. NPI

73. NPI

74. NPI

75. NPI

76. NPI

77. NPI

78. NPI

79. NPI

80. NPI

81. NPI

82. NPI

83. NPI

84. NPI

85. NPI

86. NPI

87. NPI

88. NPI

89. NPI

90. NPI

91. NPI

92. NPI

93. NPI

94. NPI

95. NPI

96. NPI

97. NPI

98. NPI

99. NPI

100. NPI

NUCC Instruction Manual available at: www.nucc.org PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

HOSPITAL CODING FORM

The CMS 1450 for Hospital Outpatient

Sample UB-04 (CMS 1450) Form — Hospital Outpatient Administration

Anytown Hospital  
100 Main Street  
Anytown, Anystate 01010

3a. PAT. CNT. #  
b. MED. REC. #  
c. FED. TAX NO.  
d. STATEMENT COVERS PERIOD FROM THROUGH

4. TYPE OF BILL

5. PATIENT NAME  
Smith, Jane

6. PATIENT ADDRESS  
123 Main Street, Anytown, Anystate 12345

7. BIRTHDATE  
11 SEX  
12 DATE  
13 HR  
14 TYPE  
15 SRC  
16 DHR  
17 STAT  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29 ACOT  
30 STATE

31. OCCURRENCE CODE  
32. OCCURRENCE DATE  
33. OCCURRENCE CODE  
34. OCCURRENCE DATE  
35. OCCURRENCE CODE  
36. OCCURRENCE DATE  
37. OCCURRENCE CODE  
38. OCCURRENCE CODE  
39. OCCURRENCE CODE  
40. OCCURRENCE CODE  
41. OCCURRENCE CODE  
42. OCCURRENCE CODE  
43. OCCURRENCE CODE  
44. OCCURRENCE CODE  
45. OCCURRENCE CODE  
46. OCCURRENCE CODE  
47. OCCURRENCE CODE  
48. OCCURRENCE CODE  
49. OCCURRENCE CODE  
50. OCCURRENCE CODE  
51. OCCURRENCE CODE  
52. OCCURRENCE CODE  
53. OCCURRENCE CODE  
54. OCCURRENCE CODE  
55. OCCURRENCE CODE  
56. OCCURRENCE CODE  
57. OCCURRENCE CODE  
58. OCCURRENCE CODE  
59. OCCURRENCE CODE  
60. OCCURRENCE CODE  
61. OCCURRENCE CODE  
62. OCCURRENCE CODE  
63. OCCURRENCE CODE  
64. OCCURRENCE CODE  
65. OCCURRENCE CODE  
66. OCCURRENCE CODE  
67. OCCURRENCE CODE  
68. OCCURRENCE CODE  
69. OCCURRENCE CODE  
70. OCCURRENCE CODE  
71. OCCURRENCE CODE  
72. OCCURRENCE CODE  
73. OCCURRENCE CODE  
74. OCCURRENCE CODE  
75. OCCURRENCE CODE  
76. OCCURRENCE CODE  
77. OCCURRENCE CODE  
78. OCCURRENCE CODE  
79. OCCURRENCE CODE  
80. OCCURRENCE CODE  
81. OCCURRENCE CODE  
82. OCCURRENCE CODE  
83. OCCURRENCE CODE  
84. OCCURRENCE CODE  
85. OCCURRENCE CODE  
86. OCCURRENCE CODE  
87. OCCURRENCE CODE  
88. OCCURRENCE CODE  
89. OCCURRENCE CODE  
90. OCCURRENCE CODE  
91. OCCURRENCE CODE  
92. OCCURRENCE CODE  
93. OCCURRENCE CODE  
94. OCCURRENCE CODE  
95. OCCURRENCE CODE  
96. OCCURRENCE CODE  
97. OCCURRENCE CODE  
98. OCCURRENCE CODE  
99. OCCURRENCE CODE  
100. OCCURRENCE CODE

42 REV. CD. 43 DESCRIPTION  
0636 N4 55513-XXX-XX ###MG  
0510 Clinic

44 HCPCS / RATE / HPPS CODE  
Q5117

45 SERV. DATE  
MMDDYY  
MMDDYY

46 SERV. UNITS  
#  
#

47 TOTAL CHARGES  
XXXXXX  
XXXXXX

48 NON-COVERED CHARGES

49

50 PAYER NAME

51 HEALTH PLAN ID

52 REL. INFO

53 ASO. BEN.

54 PRIOR PAYMENTS

55 EST. AMOUNT DUE

56 NPI

57 OTHER PRV ID

58

59 P. REL. 60 INSURED'S UNIQUE ID

61 GROUP NAME

62 INSURANCE GROUP NO.

63 TREATMENT AUTHORIZATION CODES

64 DOCUMENT CONTROL NUMBER

65 EMPLOYER NAME

66

67

68

69 ADMIT DX

70 PATIENT REASON DX

71 FPS CODE

72 ECI

73

74 PRINCIPAL PROCEDURE DATE

75

76 ATTENDING NPI

77 QUAL

78 LAST

79 FIRST

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

KANJINTI® (TRASTUZUMAB-ANNS) PRODUCT FACT SHEET

See full Indications, Boxed WARNINGS, and additional Important Safety Information on following pages.

PRODUCT INFORMATION

NDC	Description	Quantity
NDC 55513-141-01	150 mg single-dose vial of KANJINTI®	One per carton
NDC 55513-132-01	420 mg multi-dose vial of KANJINTI®	One per carton
NDC 55513-164-01	420 mg multi-dose vial (kit) of KANJINTI® and one vial of (20 mL) BWFI* <small>*bacteriostatic water for injection</small>	One per carton

STORAGE AND HANDLING REQUIREMENTS

KANJINTI® vials must be stored in the refrigerator at 2° to 8°C (36° to 46°F) until time of reconstitution. **DO NOT FREEZE.**

SHIPPING CONTAINER INFORMATION

KANJINTI® should be unpacked and refrigerated.  
KANJINTI® should not be stored in the shipping container.

PRODUCT EXPIRATION

The expiration date is printed on each dispensing pack and vial label.

PRODUCT CODE

Q5117 injection, trastuzumab-anns, biosimilar, (KANJINTI®), 10 mg

SUPPLIED AND MARKETING BY

Amgen USA Inc.  
amgen.com  
KANJINTI.com

PRODUCT RETURNS

For information and instructions regarding product returns, please contact your wholesaler or Amgen Trade Operations at 1-800-28-AMGEN (1-800-282-6436). Credit for returns is subject to Amgen's current Product Return Policy.

PRODUCT INFORMATION

Medical Information: 1-800-77-AMGEN (1-800-772-6436)

REIMBURSEMENT INFORMATION

Amgen Assist®: 1-888-4ASSIST (1-888-427-7478) or [www.AmgenAssistOnline.com](http://www.AmgenAssistOnline.com)

Please see accompanying Important Safety Information, including Boxed WARNINGS, and full Prescribing Information.

SUPPORT PROGRAMS



AMGEN Support+ | Co-Pay Program

Helping eligible patients save on out-of-pocket costs

The Amgen SupportPlus Co-Pay Program is here to help eligible commercially insured patients pay for their out-of-pocket prescription costs.

- Pay as little as **\$0 out-of-pocket\*** for each dose or cycle
- Can be applied to deductible, co-insurance, and co-payment†
- No income eligibility requirement

Please visit [www.amgenassist.com/copay](http://www.amgenassist.com/copay) for full program details and terms and conditions

\*25 out-of-pocket cost for each dose of Prolia® (denosumab) and EVENITY® (romosozumab-aqqg) through Amgen SupportPlus.

†Terms, conditions, and program maximums apply. Other restrictions may apply. See the Amgen SupportPlus Co-Pay Program Terms and Conditions for details. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.



See How We Can Help Your Patients

Offering the tools, information, and support for Amgen products that make a difference for you and your patients



AMGEN REIMBURSEMENT SPECIALISTS

Connect with an Amgen Reimbursement Counselor, or schedule a visit with a Field Reimbursement Specialist



BENEFIT VERIFICATION

Submit, store, and retrieve benefit verifications for all your patients currently on an Amgen product



AMGEN NURSE NAVIGATORS†

Single point of contact, offering personalized support to help patients and caregivers manage treatment

†Amgen Nurse Navigators are only available to patients that are prescribed certain products. Nurse Navigators are there to support, not replace, your treatment plan and do not provide medical advice, nursing, or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

CALL 1-888-4ASSIST (888-427-7478)  
Monday to Friday, 9:00 AM to 8:00 PM ET,  
OR VISIT [WWW.AMGENASSIST360.COM](http://WWW.AMGENASSIST360.COM)



#





**Please see accompanying full Important Safety Information, including Boxed WARNINGS, and Prescribing Information.**

Please visit **KANJINTI.com** for additional information and resources.

Call **1-800-77-AMGEN (1-800-772-6436)** if you have questions about ordering and accessing KANJINTI®.

#### **Reimbursement Disclaimer**

This resource is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

**References:** **1.** KANJINTI® (trastuzumab-anns) Prescribing Information, Amgen. [https://www.pi.amgen.com/united\\_states/kanjinti/kanjinti\\_pi.pdf](https://www.pi.amgen.com/united_states/kanjinti/kanjinti_pi.pdf). **2.** Herceptin® (trastuzumab) Prescribing Information [revised 2017], Genentech. **3.** Centers for Disease Control and Prevention. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). [ftp://ftp.cdc.gov/pub/Health\\_Statistics/NCHS/Publications/ICD10CM/2019/icd10cm\\_index\\_2019.pdf](ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2019/icd10cm_index_2019.pdf). Accessed April 2, 2019. **4.** Healthcare Common Procedure Coding System (HCPCS). HCPCS Code J3590. <https://hcpcs.codes/j-codes/J3590/>. Accessed April 2, 2019. **5.** American Medical Association. 2018 Professional Edition, Current Procedural Terminology (CPT) copyright 2016 American Medical Association. All rights reserved.



KANJINTI® is a registered trademark of Amgen Inc.  
© 2023 Amgen Inc. All rights reserved. USA-OCF-82134 01/23



# Resource Guide

KANJINTI® is a biosimilar to Herceptin®  
backed by Amgen expertise<sup>1</sup>

## INDICATIONS

### Adjuvant Breast Cancer

KANJINTI® is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature\*) breast cancer:

- As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel
- As part of treatment with docetaxel and carboplatin
- As a single agent following multi-modality anthracycline-based therapy

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

\*High-risk is defined as ER/PR positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3.

### Metastatic Breast Cancer

KANJINTI® is indicated:

- In combination with paclitaxel for the first line treatment of HER2-overexpressing metastatic breast cancer
- As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

### Metastatic Gastric Cancer

KANJINTI® is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease.

Select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab product.

## Boxed WARNINGS and Additional Important Safety Information

### Cardiomyopathy

- Trastuzumab products administration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens
- Evaluate left ventricular function in all patients prior to and during treatment with KANJINTI®. Discontinue KANJINTI® treatment in patients receiving adjuvant therapy and withhold KANJINTI® in patients with metastatic disease for clinically significant decrease in left ventricular function

Please see full indications on pages 2 and 3 and Important Safety Information, including Boxed WARNINGS, on pages 12 and 13, and [click here for full Prescribing Information](#).



# TABLE OF CONTENTS

---

SUPPLY .....	3
RECONSTITUTION AND PREPARATION INSTRUCTIONS .....	4
IV INFUSION DURATION, DOSING, AND SCHEDULES .....	6
CODING .....	7
PHYSICIAN CODING FORM .....	8
HOSPITAL CODING FORM .....	9
KANJINTI® PRODUCT FACT SHEET .....	10
SUPPORT PROGRAMS .....	11
IMPORTANT SAFETY INFORMATION .....	12

Amgen can provide support for institutions, including education, reimbursement assistance, and to help facilitate transitioning to KANJINTI® (trastuzumab-anns).

**CALL 1-888-4ASSIST (888-427-7478) Monday to Friday, 9:00 AM to 8:00 PM ET,  
OR VISIT AMGENASSIST360.COM**

## Boxed WARNINGS and Additional Important Safety Information (*continued*)

### Infusion Reactions; Pulmonary Toxicity

- Trastuzumab products administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration. Interrupt KANJINTI® infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue KANJINTI® for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome

### Embryo-Fetal Toxicity

- Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception

Please [click here for full Prescribing Information](#), including Boxed WARNINGS.

# SUPPLY

## SUPPLY<sup>1</sup>

KANJINTI® in powder form is a sterile, white to pale yellow, preservative-free lyophilized powder in a vial.

Each carton of KANJINTI® contains either:

- **150 mg single-dose vial of KANJINTI®**

(NDC 55513-141-01)<sup>1</sup>

- **420 mg multi-dose\* vial of KANJINTI®**

(NDC 55513-132-01)

\*Multi-dose when reconstituted with bacteriostatic water for injection

- **420 mg multi-dose<sup>†</sup> vial (kit) of KANJINTI® and one vial (20 mL) BWFI**

(NDC 55513-164-01)

<sup>†</sup>Multi-dose when reconstituted with included bacteriostatic water for injection (BWFI)



# RECONSTITUTION AND PREPARATION INSTRUCTIONS

## RECONSTITUTION OF KANJINTI® (TRASTUZUMAB-ANNS) VIALS<sup>1,2</sup>

SUPPLY AND STORAGE	
Multiple-Dose Vials*	
Reconstituted with 20 mL BWFI, <sup>†</sup> USP containing 1.1% benzyl alcohol	Diluted in infusion bag with 250 mL of 0.9% sodium chloride injection, USP
Refrigerate at	
2° to 8°C (36° to 46°F)	2° to 8°C (36° to 46°F)
Maximum time: <b>28 days</b>	Maximum time: <b>24 hours</b>

\*Single-use vial when reconstituted with Sterile Water for Injection

<sup>†</sup>Bacteriostatic water for injection, USP, containing 0.9%-1.1% benzyl alcohol as a preservative is allowable

If you have any questions about the reconstitution and preparation of KANJINTI®, refer to the package insert or call 1-800-77-AMGEN (1-800-772-6436). For additional information and resources, please visit [KANJINTI.com](http://KANJINTI.com)

### Boxed WARNINGS and Additional Important Safety Information (continued)

#### Cardiomyopathy

- Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. In a pivotal adjuvant breast cancer trial, one patient who developed CHF died of cardiomyopathy

Please see full Important Safety Information, including Boxed WARNINGS, and [click here for full Prescribing Information.](#)



# RECONSTITUTION AND PREPARATION INSTRUCTIONS

(continued)

## FOR RECONSTITUTION<sup>1</sup>

Use appropriate aseptic technique when performing the following reconstitution steps:



Using a sterile syringe, slowly inject the (20 mL) of diluent into the vial containing the lyophilized cake of KANJINTI®. The stream of diluent should be directed into the lyophilized cake. The reconstituted vial yields a solution for multiple-dose use, containing 21 mg/mL trastuzumab-anns KANJINTI® when BWFI is used to reconstitute.



Swirl the vial gently to aid reconstitution. **DO NOT SHAKE.**

Slight foaming of the product may be present upon reconstitution. Allow the vial to stand undisturbed for approximately 5 minutes.

Inspect visually for particulates and discoloration prior to administration. The solution should be free of visible particulates, clear to slightly opalescent, and colorless to pale yellow.




Store KANJINTI® reconstituted with diluent in the refrigerator at 2°C to 8°C (36°F to 46°F); discard unused KANJINTI® after 28 days. If KANJINTI® is reconstituted with SWFI without preservative, use immediately and discard any unused portion.




**DO NOT FREEZE.**

## FOR DILUTION<sup>1</sup>



Determine the dose (mg) of KANJINTI®. Calculate the volume of the 21 mg/mL reconstituted KANJINTI® solution needed, withdraw this amount from the vial and add it to an infusion bag containing 250 mL of 0.9% Sodium Chloride, USP. **DO NOT USE DEXTROSE (5%) SOLUTION.**



Gently invert the bag to mix the solution. The solution of KANJINTI® for infusion, diluted in polyvinylchloride or polyethylene bags containing 0.9% Sodium Chloride Injection, USP, should be stored at 2° to 8°C (36° to 46°F) for no more than 24 hours prior to use. This storage time is additional to the time allowed for the reconstituted vials.<sup>1</sup>



**DO NOT FREEZE.**

## Boxed WARNINGS and Additional Important Safety Information (continued)

- Trastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death
- Trastuzumab products can also cause asymptomatic decline in left ventricular ejection fraction (LVEF)
- Discontinue KANJINTI® treatment in patients receiving adjuvant breast cancer therapy and withhold KANJINTI® in patients with metastatic disease for clinically significant decrease in left ventricular function



## IV INFUSION DURATION, DOSING, AND SCHEDULES

### ADJUVANT TREATMENT, BREAST CANCER

#### WITH PACLITAXEL OR DOCETAXEL



#### WITH DOCETAXEL AND CARBOPLATIN




#### AS SINGLE AGENT\*



\*Within 3 weeks following completion of all chemotherapy.

### METASTATIC BREAST CANCER

#### AS SINGLE AGENT OR WITH PACLITAXEL



### METASTATIC GASTRIC CANCER

#### AS SINGLE AGENT



IV = intravenous; QW = once a week; Q3W = once every 3 weeks.

### Boxed WARNINGS and Additional Important Safety Information (*continued*)

#### Cardiac Monitoring

- Evaluate cardiac function prior to and during treatment. For adjuvant breast cancer therapy, also evaluate cardiac function after completion of KANJINTI®
- Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan

**Please see full Important Safety Information, including Boxed WARNINGS, and click here for full Prescribing Information.**

# GENERAL CODING INFORMATION

## NATIONAL DRUG CODES (NDCs)<sup>1</sup>

<b>BILLING</b>	Each single-dose carton contains one vial of KANJINTI® (150 mg trastuzumab-anns) NDC 55513-141-01
	Each multi-dose carton contains one vial of KANJINTI® (420 mg trastuzumab-anns) NDC 55513-132-01
	Each multi-dose carton (kit) contains one vial of KANJINTI® (420 mg trastuzumab-anns) and one vial of BWFI (20 mL) NDC 55513-164-01

## BREAST CANCER

<b>ICD-10-CM<sup>3</sup></b>	<b>Malignant neoplasm of the breast</b>	
	<b>Female breast</b>	<b>Male breast</b>
	C50.011 - C50.012, C50.019 C50.111 - C50.112, C50.119 C50.211 - C50.212, C50.219 C50.311 - C50.312, C50.319 C50.411 - C50.412, C50.419 C50.511 - C50.512, C50.519 C50.611 - C50.612, C50.619 C50.811 - C50.812, C50.819 C50.911 - C50.913, C50.919	C50.021 - C50.022, C50.029 C50.121 - C50.122, C50.129 C50.221 - C50.222, C50.229 C50.321 - C50.322, C50.329 C50.421 - C50.422, C50.429 C50.521 - C50.522, C50.529 C50.621 - C50.622, C50.629 C50.821 - C50.822, C50.829 C50.921 - C50.922, C50.929
<b>HCPCS<sup>4</sup></b>	Q5117 injection, trastuzumab-anns, biosimilar, (KANJINTI®), 10 mg	
<b>CPT<sup>5</sup></b>	<b>96413:</b> Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug.	
	<b>96415:</b> Chemotherapy administration, intravenous infusion technique; each additional hour. Must be listed separately in addition to code for primary procedure.	
	<b>96417:</b> Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to one hour. Must be listed separately in addition to code for primary procedure.	

## METASTATIC GASTRIC CANCER

<b>ICD-10-CM<sup>3</sup></b>	<b>Malignant neoplasm of the stomach</b>				
	C16.0 C16.1	C16.2 C16.3	C16.4 C16.5	C16.6 C16.7	C16.8 C16.9
<b>HCPCS<sup>4</sup></b>	Q5117 injection, trastuzumab-anns, biosimilar, (KANJINTI®), 10 mg				
<b>CPT<sup>5</sup></b>	<b>96413:</b> Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug.				
	<b>96415:</b> Chemotherapy administration, intravenous infusion technique; each additional hour. Must be listed separately in addition to code for primary procedure.				
	<b>96417:</b> Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to one hour. Must be listed separately in addition to code for primary procedure.				

The information provided in this document is of a general nature and for informational purposes only; it is not intended to be comprehensive or instructive. Coding and coverage policies change periodically and often without warning. The healthcare provider is solely responsible for determining coverage and reimbursement parameters and appropriate coding for his/her own patients and procedures. In no way should the information provided in this document be considered a guarantee of coverage or reimbursement for any product or service.

BWFI = bacteriostatic water for injection; ICD = international classification of diseases;

HCPCS = healthcare common procedure coding system; CPT = current procedural terminology.

## Boxed WARNINGS and Additional Important Safety Information (continued)

- Monitor frequently for decreased left ventricular function during and after KANJINTI® treatment
- Monitor more frequently if KANJINTI® is withheld for significant left ventricular cardiac dysfunction



# PHYSICIAN CODING FORM

## The CMS 1500 for Physician Office

Sample CMS 1500 Form — Physician Office Administration

HEALTH INSURANCE CLAIM FORM									
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12									
<div> <div> <input type="checkbox"/> PICA                 </div> <div> <input type="checkbox"/> PICA                 </div> </div>									
1. MEDICARE <input type="checkbox"/> MEDICAID <input type="checkbox"/> TRICARE <input type="checkbox"/> CHAMPVA <input type="checkbox"/> GROUP HEALTH PLAN <input type="checkbox"/> FECA BLK LUNG <input type="checkbox"/> OTHER <input type="checkbox"/> (Medicare#) (Medicaid#) (ID#/DoD#) (Member ID#) (ID#) (ID#) (ID#)					1a. INSURED'S I.D. NUMBER (For Program in Item 1)				
2. PATIENT'S NAME (Last Name, First Name, Middle Initial) <b>Doe, John D</b>					3. PATIENT'S BIRTH DATE MM DD YY <b>XX XX XX</b> SEX M <input type="checkbox"/> F <input type="checkbox"/>				
5. PATIENT'S ADDRESS (No., Street) <b>5555 Any Street</b>					6. PATIENT RELATIONSHIP TO INSURED Self <input type="checkbox"/> Spouse <input type="checkbox"/> Child <input type="checkbox"/> Other <input type="checkbox"/>				
CITY <b>Anytown</b> STATE <b>AS</b>					7. INSURED'S ADDRESS (No., Street)				
ZIP CODE <b>01010</b> TELEPHONE (Include Area Code) <b>(XXX) XXX-XXXX</b>					CITY STATE				
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)					10. IS PATIENT'S CONDITION RELATED TO:				
a. OTHER INSURED'S POLICY OR GROUP NUMBER					a. EMPLOYMENT? (Current or Previous) YES <input type="checkbox"/> NO <input type="checkbox"/>				
b. RESERVED FOR NUCC USE					b. AUTO ACCIDENT? YES <input type="checkbox"/> NO <input type="checkbox"/> PLACE (State)				
c. RESERVED FOR NUCC USE					c. OTHER ACCIDENT? YES <input type="checkbox"/> NO <input type="checkbox"/>				
d. INSURANCE PLAN NAME OR PROGRAM NAME					10d. CLAIM CODES (Designated by NUCC)				
<b>PRODUCT CODE (BOX 24D)</b> Use Q5117 injection, trastuzumab-anns, biosimilar, [KANJINTI®], 10 mg					<b>DIAGNOSIS CODE (BOX 21)</b> Document appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Line A — primary diagnosis code.				
SIGNED _____ DATE _____					<b>DIAGNOSIS CODE (BOX 24E)</b> Specify diagnosis, from Box 21, relating to each CPT/HCPCS code listed in Box 24D.				
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) MM DD YY <b>XX XX XX</b> QUAL.					15. OTHER DATE MM DD YY				
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE					17a. NPI				
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)									
<b>Brand Name Molecule Name NDC ### Dose Administered</b>									
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to service line below (24)									
<b>XXX.XX</b>									
A. B. C. D. E. F. G. H. I. J. K. L.									
24. A. DATE(S) OF SERVICE From To B. PLACE OF SERVICE C. D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) E. DIAGNOSIS POLITER F. \$ CHARGES G. DAYS OR UNITS H. EPSON Family Plan I. ID. J. RENDERING PROVIDER ID. #									
1 <b>N4 55513-XXX-XX ###MG</b> <b>Q5117</b> <b>A</b> <b>XXX XX #</b>									
2 <b>MM DD YY MM DD YY 11</b> <b>96XXX</b> <b>A</b> <b>XXX XX #</b>									
3									
4									
5									
6									
<b>PROCEDURE CODE (BOX 24D)</b> Use CPT code representing procedure performed. Healthcare providers should consult the payer or Medicare contractor to determine which code is most appropriate for administration of KANJINTI®.									
25. FEDERAL TAX I.D. NUMBER									
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)									
32. SERVICE FACILITY LOCATION INFORMATION									
33. BILLING PROVIDER INFO & PH # ( )									
28. TOTAL CHARGE \$ 29. AMOUNT PAID \$ 30. Rsvd for NUCC Use									
SIGNED _____ DATE _____ a. NPI b.									

NUCC Instruction Manual available at: [www.nucc.org](http://www.nucc.org) PLEASE PRINT OR TYPE APPROVED OMB-0938-1197 FORM 1500 (02-12)

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.



## The CMS 1450 for Hospital Outpatient

[illegible]

**KANJINTI®**  
(trastuzumab-anns)  
For Injection 420mg/ vial multiple dose

# KANJINTI® (TRASTUZUMAB-ANNS) PRODUCT FACT SHEET

See full Indications, Boxed WARNINGS, and additional Important Safety Information on following pages.

## PRODUCT INFORMATION

NDC	Description	Quantity
NDC 55513-141-01	150 mg single-dose vial of KANJINTI®	One per carton
NDC 55513-132-01	420 mg multi-dose vial of KANJINTI®	One per carton
NDC 55513-164-01	420 mg multi-dose vial (kit) of KANJINTI® and one vial of (20 mL) BWFI* *bacteriostatic water for injection	One per carton

## STORAGE AND HANDLING REQUIREMENTS

KANJINTI® vials must be stored in the refrigerator at 2° to 8°C (36° to 46°F) until time of reconstitution. **DO NOT FREEZE.**

## SHIPPING CONTAINER INFORMATION

KANJINTI® should be unpacked and refrigerated.

KANJINTI® should not be stored in the shipping container.

## PRODUCT EXPIRATION

The expiration date is printed on each dispensing pack and vial label.

## PRODUCT CODE

Q5117 injection, trastuzumab-anns, biosimilar, (KANJINTI®), 10 mg

## SUPPLIED AND MARKETING BY

Amgen USA Inc.

amgen.com

KANJINTI.com

## PRODUCT RETURNS

For information and instructions regarding product returns, please contact your wholesaler or Amgen Trade Operations at 1-800-28-AMGEN (1-800-282-6436). Credit for returns is subject to Amgen's current Product Return Policy.

## PRODUCT INFORMATION

Medical Information: 1-800-77-AMGEN (1-800-772-6436)

## REIMBURSEMENT INFORMATION

Amgen Assist®: 1-888-4ASSIST (1-888-427-7478) or [www.AmgenAssistOnline.com](http://www.AmgenAssistOnline.com)

Please see full Important Safety Information, including Boxed WARNINGS, and [click here for full Prescribing Information.](#)

## SUPPORT PROGRAMS

### AMGEN<sup>®</sup> Support<sup>+</sup> | Co-Pay Program



### Helping eligible patients save on out-of-pocket costs

The Amgen SupportPlus Co-Pay Program is here to help eligible commercially insured patients pay for their out-of-pocket prescription costs.

- Pay as little as **\$0 out-of-pocket\*** for each dose or cycle
- Can be applied to deductible, co-insurance, and co-payment<sup>†</sup>
- No income eligibility requirement

Visit [Amgen SupportPlus Co-Pay Program](#) for full program details and terms and conditions

\*25 out-of-pocket cost for each dose of Prolia<sup>®</sup> (denosumab) and EVENITY<sup>®</sup> (romosozumab-aqqg) through Amgen SupportPlus.

<sup>†</sup>Terms, conditions, and program maximums apply. Other restrictions may apply. See the Amgen SupportPlus Co-Pay Program Terms and Conditions for details. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.



## See How We Can Help Your Patients

Offering the tools, information, and support for Amgen products that make a difference for you and your patients



### AMGEN REIMBURSEMENT SPECIALISTS

Connect with an Amgen Reimbursement Counselor, or schedule a visit with a Field Reimbursement Specialist



### BENEFIT VERIFICATION

Submit, store, and retrieve benefit verifications for all your patients currently on an Amgen product



### AMGEN NURSE NAVIGATORS<sup>‡</sup>

Single point of contact, offering personalized support to help patients and caregivers manage treatment

<sup>‡</sup>Amgen Nurse Navigators are only available to patients that are prescribed certain products. Nurse Navigators are there to support, not replace, your treatment plan and do not provide medical advice, nursing, or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

**CALL 1-888-4ASSIST (888-427-7478)**  
**Monday to Friday, 9:00 AM to 8:00 PM ET,**  
**OR VISIT [WWW.AMGENASSIST360.COM](http://WWW.AMGENASSIST360.COM)**



# IMPORTANT SAFETY INFORMATION

---

## Boxed WARNINGS and Additional Important Safety Information

### Cardiomyopathy

- Trastuzumab products administration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens
- Evaluate left ventricular function in all patients prior to and during treatment with KANJINTI®. Discontinue KANJINTI® treatment in patients receiving adjuvant therapy and withhold KANJINTI® in patients with metastatic disease for clinically significant decrease in left ventricular function

### Infusion Reactions; Pulmonary Toxicity

- Trastuzumab products administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration. Interrupt KANJINTI® infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue KANJINTI® for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome

### Embryo-Fetal Toxicity

- Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception

### Cardiomyopathy

- Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. In a pivotal adjuvant breast cancer trial, one patient who developed CHF died of cardiomyopathy

- Trastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death
- Trastuzumab products can also cause asymptomatic decline in left ventricular ejection fraction (LVEF)
- Discontinue KANJINTI® treatment in patients receiving adjuvant breast cancer therapy and withhold KANJINTI® in patients with metastatic disease for clinically significant decrease in left ventricular function

### Cardiac Monitoring

- Evaluate cardiac function prior to and during treatment. For adjuvant breast cancer therapy, also evaluate cardiac function after completion of KANJINTI®
- Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan
- Monitor frequently for decreased left ventricular function during and after KANJINTI® treatment
- Monitor more frequently if KANJINTI® is withheld for significant left ventricular cardiac dysfunction

### Infusion Reactions

- KANJINTI® administration can result in serious and fatal infusion reactions
- Symptoms usually occur during or within 24 hours of KANJINTI® administration
- Interrupt KANJINTI® infusion for dyspnea or clinically significant hypotension
- Monitor patients until symptoms completely resolve
- Discontinue KANJINTI® for infusion reactions manifesting as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.

Please [click here for full Prescribing Information, including Boxed WARNINGS.](#)





## IMPORTANT SAFETY INFORMATION (*continued*)

---

### **Strongly consider permanent discontinuation in all patients with severe infusion reactions**

- Infusion reactions consist of a symptom complex characterized by fever and chills, and on occasion include nausea, vomiting, pain (in some cases at tumor sites), headache, dizziness, dyspnea, hypotension, rash, and asthenia

### **Embryo-Fetal Toxicity**

- **Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception**
- Verify the pregnancy status of females of reproductive potential prior to the initiation of KANJINTI®
- Advise pregnant women and females of reproductive potential that exposure to KANJINTI® during pregnancy or within 7 months prior to conception can result in fetal harm
- Advise females of reproductive potential to use effective contraception during treatment and for at least 7 months following the last dose of KANJINTI®. Advise female patients to contact their healthcare provider with a known or suspected pregnancy
- Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for KANJINTI® treatment and any potential adverse effects on the breastfed child from KANJINTI® or from the underlying maternal condition

### **Pulmonary Toxicity**

- **Trastuzumab products can result in serious and fatal pulmonary toxicity**, which includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, noncardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress

syndrome, and pulmonary fibrosis. Such events can occur as sequelae of infusion reactions

- Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest, appear to have more severe toxicity
- Discontinue KANJINTI® in patients experiencing pulmonary toxicity

### **Exacerbation of Chemotherapy-Induced Neutropenia**

- In randomized, controlled clinical trials, the per-patient incidences of NCI-CTC Grade 3-4 neutropenia and of febrile neutropenia were higher in patients receiving trastuzumab in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone. The incidence of septic death was similar among patients who received trastuzumab and those who did not

### **Most Common Adverse Reactions**

- The most common adverse reactions associated with trastuzumab products in breast cancer were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia
- The most common adverse reactions associated with trastuzumab products in metastatic gastric cancer were neutropenia, diarrhea, fatigue, anemia, stomatitis, weight loss, upper respiratory tract infections, fever, thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia.

You may report side effects to the FDA at (800) FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). You may also report side effects to Amgen at 1-800-772-6436.

**Please click here for full Prescribing Information, including Boxed WARNINGS.**





**Please see full Important Safety Information, including Boxed WARNINGS, and [click here for full Prescribing Information.](#)**

Please visit **KANJINTI.com** for additional information and resources.

Call **1-800-77-AMGEN (1-800-772-6436)** if you have questions about ordering and accessing KANJINTI®.

#### **Reimbursement Disclaimer**

This resource is intended as a reference for coding and billing for product and associated services. It is not intended to be directive; the use of the recommended codes does not guarantee reimbursement. Healthcare providers may deem other codes or policies more appropriate and should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Healthcare providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

**References:** **1.** KANJINTI® (trastuzumab-anns) Prescribing Information, Amgen. [https://www.pi.amgen.com/united\\_states/kanjinti/kanjinti\\_pi.pdf](https://www.pi.amgen.com/united_states/kanjinti/kanjinti_pi.pdf). **2.** Herceptin® (trastuzumab) Prescribing Information [revised 2017], Genentech. **3.** Centers for Disease Control and Prevention. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). [ftp://ftp.cdc.gov/pub/Health\\_Statistics/NCHS/Publications/ICD10CM/2019/icd10cm\\_index\\_2019.pdf](ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2019/icd10cm_index_2019.pdf). Accessed April 2, 2019. **4.** Healthcare Common Procedure Coding System (HCPCS). HCPCS Code J3590. <https://hcpcs.codes/j-codes/J3590/>. Accessed April 2, 2019. **5.** American Medical Association. 2018 Professional Edition, Current Procedural Terminology (CPT) copyright 2016 American Medical Association. All rights reserved.



KANJINTI® is a registered trademark of Amgen Inc.  
© 2023 Amgen Inc. All rights reserved. USA-OCF-82134 01/23